Real‐World Use of Lecanemab in Patients With Early Alzheimer’s Disease in the United States: a Case Series Review

Abstract

Background: Lecanemab‐irmb (LEQEMBI®) is indicated for the treatment of patients with Alzheimer’s disease (AD) in the mild cognitive impairment (MCI) or mild dementia stage.

The paper